Developing a vaccine to prevent malaria caused by Plasmodium vivax.

Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine

NIH-funded research University of South Florida · NIH-10994661

This study is working on a new vaccine to help prevent malaria caused by Plasmodium vivax, especially for people in areas with limited healthcare, by finding ways to stop the parasite from infecting the liver and causing symptoms.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionUniversity of South Florida NIH-funded
Lab location1 site (Tampa, United States)
Project IDNIH-10994661 on NIH RePORTER

What this research studies

This research focuses on creating a vaccine to combat Plasmodium vivax, a major cause of malaria, particularly in regions with limited healthcare access. The project aims to identify and validate a combination of specific antigens that can effectively prevent the infection from progressing through its various stages. By utilizing innovative laboratory techniques, the researchers will assess how these antigens can inhibit the parasite's ability to infect the liver and subsequently cause malaria symptoms. This approach is designed to address the unique challenges posed by the dormant stages of the parasite, which can lead to relapses in infected individuals.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals living in malaria-endemic regions, particularly those at risk of Plasmodium vivax infection.

Not a fit: Patients who do not reside in malaria-endemic areas or those who are not at risk for Plasmodium vivax infection may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to a highly effective vaccine that significantly reduces the incidence of malaria caused by Plasmodium vivax, improving health outcomes in affected populations.

How similar studies have performed: While there have been various vaccine development efforts for malaria, this specific approach targeting Plasmodium vivax is relatively novel and aims to address unique challenges associated with this parasite.

Where this research is happening

Tampa, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.